InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.920 0.01 (0.13%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$400 SCENESSE Commercialisation Update 5 Jun 2015 9:13AM $2.950 $7.920 risen by 168.47%
$400 Clinuvel announces innovative melanocortin 5 May 2015 3:17PM $2.860 $7.920 risen by 176.92%
$400 Appendix 4C - quarterly 27 Apr 2015 9:27AM $2.880 $7.920 risen by 175%
$400 S&P DJ Indices Announces March Quarterly Review 6 Mar 2015 8:44AM $3.140 $7.920 risen by 152.23%
$400 Half Yearly Report and Accounts 25 Feb 2015 12:50PM n/a $7.920 n/a
$400 Appendix 4C - quarterly 30 Jan 2015 3:57PM $3.770 $7.920 risen by 110.08%
$400 European Commission approves SCENESSE 23 Dec 2014 10:32AM $4.370 $7.920 risen by 81.24%
$400 Appendix 4C - quarterly 29 Oct 2014 9:27AM $5.000 $7.920 risen by 58.40%
$400 Appendix 4C - quarterly 29 Oct 2014 9:27AM $5.000 $7.920 risen by 58.40%
$400 SCENESSE attains breakthrough European Market Authorisation 27 Oct 2014 10:06AM $4.290 $7.920 risen by 84.62%
$400 Trading Halt 24 Oct 2014 9:20AM $2.620 $7.920 risen by 202.29%
$400 EMA Oral Explanation Update 26 Sep 2014 8:55AM $3.300 $7.920 risen by 140%
$400 Clinuvel enters a joint venture with Biotech Lab Singapore 19 Sep 2014 12:18PM $4.720 $7.920 risen by 67.80%
$400 JAMA Dermatology publishes SCENESSE vitiligo study results 19 Sep 2014 12:00PM $4.720 $7.920 risen by 67.80%
$400 Response to ASX Price Query 16 Sep 2014 8:55AM $4.180 $7.920 risen by 89.47%
$400 Preliminary Final Report 25 Aug 2014 9:28AM $2.450 $7.920 risen by 223.27%
$400 Clinuvel declines unsolicited proposal from Retrophin 8 Aug 2014 9:33AM $2.190 $7.920 risen by 261.64%
$400 Appendix 4C - quarterly 31 Jul 2014 9:44AM $2.150 $7.920 risen by 268.37%
$400 Clinuvel receives an unsolicited bid for the Company 28 Jul 2014 9:38AM $2.180 $7.920 risen by 263.30%
$400 US orphan-drug designation in Hailey-Hailey Disease 22 May 2014 10:41AM $1.455 $7.920 risen by 444.33%
$400 Management Update 19 May 2014 9:12AM $1.420 $7.920 risen by 457.75%
$400 Clinuvel placement 14 May 2014 9:40AM $1.500 $7.920 risen by 428%
$400 Trading Halt 12 May 2014 9:50AM $1.500 $7.920 risen by 428%
$400 Phase II vitiligo study commences in Singapore 6 May 2014 9:55AM $1.600 $7.920 risen by 395%
$400 Appendix 4C - quarterly 17 Apr 2014 8:29AM $1.630 $7.920 risen by 385.89%

701 - 725 of 880 results

Page 29 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.